- Oops!Something went wrong.Please try again later.
Antony Mattessich has been the CEO of Ocular Therapeutix, Inc. (NASDAQ:OCUL) since 2017, and this article will examine the executive's compensation with respect to the overall performance of the company. This analysis will also assess whether Ocular Therapeutix pays its CEO appropriately, considering recent earnings growth and total shareholder returns.
How Does Total Compensation For Antony Mattessich Compare With Other Companies In The Industry?
Our data indicates that Ocular Therapeutix, Inc. has a market capitalization of US$1.6b, and total annual CEO compensation was reported as US$2.1m for the year to December 2019. That's a notable decrease of 19% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$582k.
On comparing similar companies from the same industry with market caps ranging from US$1.0b to US$3.2b, we found that the median CEO total compensation was US$4.7m. This suggests that Antony Mattessich is paid below the industry median. What's more, Antony Mattessich holds US$2.1m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
Talking in terms of the industry, salary represented approximately 25% of total compensation out of all the companies we analyzed, while other remuneration made up 75% of the pie. Our data reveals that Ocular Therapeutix allocates salary more or less in line with the wider market. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
A Look at Ocular Therapeutix, Inc.'s Growth Numbers
Over the past three years, Ocular Therapeutix, Inc. has seen its earnings per share (EPS) grow by 4.0% per year. It achieved revenue growth of 394% over the last year.
It's hard to interpret the strong revenue growth as anything other than a positive. And in that context, the modest EPS improvement certainly isn't shabby. We wouldn't say this is necessarily top notch growth, but it is certainly promising. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.
Has Ocular Therapeutix, Inc. Been A Good Investment?
Most shareholders would probably be pleased with Ocular Therapeutix, Inc. for providing a total return of 368% over three years. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.
As previously discussed, Antony is compensated less than what is normal for CEOs of companies of similar size, and which belong to the same industry. However, shareholder returns are rock solid over the past three years, and that’s undoubtedly a good sign. Considering this fine result for investors, we believe CEO compensation to be apt.
It is always advisable to analyse CEO pay, along with performing a thorough analysis of the company's key performance areas. We identified 2 warning signs for Ocular Therapeutix (1 is concerning!) that you should be aware of before investing here.
Switching gears from Ocular Therapeutix, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email firstname.lastname@example.org.